Studies on Solid Dispersed Etoricoxib with Newer CarriersAuthor(s): A. Prameels Rani, R. Santosh Kumar and N. Sarat Babu
Etoricoxib (ETO) is a non-steroidal anti-inflammatory drug, which is widely used in symptomatic relief of osteoarthritis and rheumatoid arthritis. One of the major problems of this drug is its low solubility in biological fluids, which results into poor bioavailability after oral administration. Therefore, solid dispersion of ETO with newer carriers i. e., croscarmellose sodium (CCS) and crospovidone (CP) were prepared using CCS and CP in three ratios (1 : 1, 1 : 2 and 1 : 3) employing physical mixing method and solvent evaporation method. The drug release profile for pure drug as such and its solid dispersions was determined. ETO was released at much higher rate from its solid dispersions as compared to that of pure drug. Faster dissolution rate was observed in drug : CCS (1 : 3 ) prepared by co-evaporation method. The increase in dissolution rate of drug may be due to increase of wettability, hydrophilic nature of carrier and also due to reduction in drug crystallinity, which is supported by DSC thermograms.